Novo Nordisk, Eli Lilly rise after Viking obesity trial data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's sales and AI chip forecast comes in below expectations, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wall Street ends lower as Middle East tensions escalate
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
Raymond James Reiterates Strong Buy Rating on Viking Therapeutic (VKTX), PT $122
August 19, 2025 2:10 PM EDTRaymond James analyst Steve Seedhouse reiterated a Strong Buy rating and $122.00 price target on Viking Therapeutic (NASDAQ: VKTX).
The analyst comments "Viking reported topline data from its Phase 2 study evaluating oral VK2735 in obesity showing dose-dependent weight loss over 13 weeks reaching reductions of up to 12.2% (10.9% placeboadjusted, p... More
Morgan Stanley Reiterates Overweight Rating on Viking Therapeutic (VKTX)
August 19, 2025 1:20 PM EDTMorgan Stanley analyst Michael E Ulz reiterated an Overweight rating and $98.00 price target on Viking Therapeutic (NASDAQ: VKTX).
The analyst comments "Oral VK2735 weigh loss above the ~8% bar at the highest dose (120mg: 12.2%) and inline/above at lower doses (30mg/60mg: 7.0%/8.7%).... More
Jefferies on Viking Therapeutic (VKTX): 'We think the market is overreacting'
August 19, 2025 1:17 PM EDTJefferies analyst Roger Song reiterated a Buy rating and $101.00 price target on Viking Therapeutic (NASDAQ: VKTX).
The analyst comments "Bottom line. We think the market is overreacting on GI AE/ discontinuation profile, underappreciating that it could be modulated by dosing optimization ("start low, go... More
H.C. Wainwright Keeps PT at $102 on Viking Therapeutic (VKTX), 'Varying Sentiments Flying Around, But We Are Happy
August 19, 2025 12:13 PM EDTH.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $102.00 price target on Viking Therapeutic (NASDAQ: VKTX).
The analyst comments "Phase 2 oral VK2735 delivers encouraging weight loss; market focus shifts to tolerability and competition. This morning, Viking announced positive topline results from its Phase 2 VENTURE-Oral Dosing Trial of oral VK2735 for weight loss. While we view the weight loss results as encouraging (see topline data below) and see the tolerability profile as something that can be optimized in future trials, we want to highlight a few contributing factors that we believe... More
Stifel on Viking Therapeutic (VKTX) Sell-Off: 'an over-reaction to the successful Ph.2 VENTURE-Oral (13-week) outcome'
August 19, 2025 12:09 PM EDTStifel analyst Samimy Annabel reiterated a Buy rating and $95.00 price target on Viking Therapeutic (NASDAQ: VKTX)
The analyst comments "We reiterate our Buy on VKTX, $95 TP following what we think is an over-reaction to the successful Ph.2 VENTURE-Oral (13-week) outcome,... More
Truist Securities Reiterates Buy Rating on Viking Therapeutic (VKTX)
August 19, 2025 9:51 AM EDTTruist Securities analyst Joon Lee reiterated a Buy rating and $75.00 price target on Viking Therapeutic (NASDAQ: VKTX).
The analyst comments "VKTX reported topline data from Ph2 VENTURE-Oral showing impressive pbo-adj weight loss of 5.7%, 7.4%, 9.8% and 10.9% for 30mg, 60mg, 90mg and 120mg, respectively at week 13. This is competitive to oral semaglutide 25mg (4Q25 PDUFA) which showed ~4% pbo-adj weight loss at week 12 (Exhibit 1). We think oral sema 25mg is the right comp as both are peptides with similar SQ to oral strategy (same molecule in different... More
